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Background. Nephrotoxicity of calcineurin inhibitors (CNIs) is partially responsible for the development of chronic
allograft nephropathy (CAN). Sirolimus has demonstrated its potential to substitute for CNIs because it lacks signifi-
cant nephrotoxicity and shows a short-term immunosuppressive capacity comparable with that of cyclosporine. This
results in the maintenance of better renal function when cyclosporine is eliminated, but it has not been demonstrated
whether this benefit is associated with an improvement in the pathologic substrate and a reduction in CAN.
Methods.We analyzed pretransplant and 1-year renal-allograft biopsies from 64 patients enrolled in a multicenter trial.
Patients received cyclosporine and sirolimus during the first 3 months after transplant and were then randomly
assigned to continue with cyclosporine or have it withdrawn. Histologic chronic allograft lesions were compared
between groups.
Results. The percentage of patients in whom chronic pathologic lesions progressed was lower in the group of cyclo-
sporine elimination. Significant differences were observed in chronic interstitial and tubular lesions (70% vs. 40.9%
[P0.05] and 70% vs. 47.8% [P0.05], respectively), whereas no differences were observed in acute lesions (subclinical
rejection). Prevalence of CAN at 1 year was lower in this group, as was the severity and incidence of new cases (P0.05).
Conclusions. Early cyclosporine withdrawal associated with sirolimus administration is followed by an improvement
in renal function, a reduction in the progression of chronic pathologic allograft lesions, and a lower incidence of new
cases and severity of CAN during the first year after transplantation. This benefit may result in better long-term graft
outcome.
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(Transplantation 2004;78: 1312–1318)
G iven the considerably high short-term success rate ob-tained with conventional immunosuppressive drugs
(calcineurin inhibitors [CNIs]), the objectives in the develop-
ment of new drugs during the last few years have focused on
long-term results, specifically on the prevention of chronic
graft damage (1). Chronic allograft nephropathy (CAN) is the
main cause of graft loss after the first year of transplantation,
with a prevalence of 60% to 70% in protocol biopsies at 2
years after transplantation in patients receiving CNIs, either
cyclosporine A (CsA) or tacrolimus, without significant dif-
ferences between the drugs (2). The role of these drugs in the
development of CAN and subsequent long-term graft sur-
vival seems to be of major importance because of their neph-
rotoxic effect (3).
The use of new drugs with similar immunosuppressive
capacity but without the nephrotoxic effect may yield a con-
siderable advance in increasing long-term graft survival.
Sirolimus (SRL, rapamycin, Rapamune) has shown similar
efficacy to CsA when used alone with respect to graft rejection
rates and short-term graft survival in combination with either
steroids and azathioprine (AZA) (4) or steroids and myco-
phenolate mofetil (5). Similar results have been observed
when adding induction therapy with basiliximab (6). In ad-
dition, significantly better renal function has been consis-
tently observed in patients treated with SRL but without CNIs
(4 –7). The association of CsA and SRL has a synergistic and
potent immunosuppressive effect with very low rejection
rates, but SRL appears to potentiate CsA nephrotoxicity be-
cause of a pharmacokinetic interaction. Clinical trials analyz-
ing this combination showed worse renal function in the
groups in which the two drugs were combined compared
with the control group of CsA plus AZA or placebo (8, 9).
With the objective to obtain a low rejection rate and the
minimization of the long-term deleterious effects of CsA
nephrotoxicity, a multicenter, randomized, phase 3 trial at 5
years is currently ongoing in 57 centers in Europe, Canada,
and Australia, with a total of 525 patients enrolled (The Ra-
pamune Maintenance Regimen [RMR] Study). This trial
compares a control arm (group A) using CsA, fixed doses of
SRL, and steroids with a study arm (group B) that includes
CsA, concentration-controlled SRL, and steroids with elimi-
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nation of CsA at 3 months after transplantation. The initial
results from this trial have been previously published and
demonstrated significantly better graft function (lower serum
creatinine and higher calculated glomerular filtration rate) at
1 year in group B (10). However, it has not yet been clearly
demonstrated whether this improvement in renal function is
a consequence of a hemodynamic improvement caused by
the prevention of CsA functional vascular effects or whether
the initial expression of a reduction in chronic tubulointer-
stitial and vascular damage may be responsible for a reduc-
tion in the occurrence or severity of CAN in the long term and
a subsequent increase in allograft survival.
We previously attempted to address this question in a
substudy of the RMR trial. We evaluated 140 renal biopsies in
patients with a functioning allograft at 1 year, corresponding
with the baseline (pretransplant) and 1-year biopsies of the 70
patients recruited in the 10 centers participating in Spain and
Portugal (11). In that substudy, we performed a retrospective
analysis of the information supplied by the 10 local patholo-
gists (according to the Banff ’95 classification) and observed a
lower rate of progression of chronic allograft pathologic le-
sions when CsA was eliminated. This type of analysis, how-
ever, had implicit methodological difficulties to overcome.
We could not verify that local pathologists read the biopsies in
a blinded manner with respect to treatment arm and time of
biopsy. Some lesions could have been interpreted differently,
whether they appeared in the pretransplant biopsy or 1-year
biopsy. Furthermore, the participation of 10 different pathol-
ogists in the interpretation of biopsies may have been respon-
sible for a significant interobserver variation in the interpre-
tation of the existence and severity of elemental chronic
lesions. These shortcomings have been extensively evaluated
by Furness and Taub (12) in the Convergence Of European
Renal Transplant Pathology Assessment Procedures (CERT-
PAP) Project, who recommend caution when interpreting
biopsy results between institutions.
Therefore, we performed a prospective and more pro-
found reanalysis of the renal biopsies of this subgroup of pa-
tients, amplifying the histologic analysis, which was now per-
formed by a central blinded pathologist. This article presents
the results of this reanalysis comparing the severity of chronic
pathologic allograft lesions in the two treatment groups.
MATERIALS ANDMETHODS
Rapamune Maintenance Regimen Trial
The RMR Trial is a multicenter, randomized, open-
label study that was initiated in May 1998 at 57 centers in
Europe, Canada, and Australia. All centers obtained approval
from their local ethics committees, and each patient enrolled
signed an informed consent form before transplantation. Im-
munosuppression included CsA, SRL at fixed doses (2 mg/
day), and steroids for all patients during the first 3 months
after transplantation. Patients were then randomly assigned
to one of two treatment arms: patients in group A continued
receiving CsA, SRL 2 mg, and steroids, whereas patients in
group B had CsA progressively decreased and then eliminated
in approximately 4 to 6 weeks and SRL increased to maintain
SRL trough levels in the range of 16 to 24 ng/mL by high-
performance liquid chromatography-ultraviolet (HPLC-
UV) or HPLC-mass spectrometry methods (20 to 30 ng/mL
by enzyme-linked immunoadsorbent assay method). Pa-
tients with Banff grade III acute rejection or vascular rejection
in the 4 weeks before randomization, dialysis dependency,
serum creatinine greater than 400 mol/L, or inadequate re-
nal function to support CsA elimination were excluded from
randomization. Patients underwent a pretransplant biopsy, a
second biopsy at 1 year after transplantation, and a third bi-
opsy at 3 years after transplantation. This study remains on-
going, with follow-up of patients through the fifth year after
transplantation. Details of the study design and clinical re-
sults at 1 year were published by Johnson et al. (10), and
additional information with follow-up at 2 years has been
published recently by Oberbauer et al. (13).
Patients
All 96 patients enrolled in the RMR Trial centers in
Spain and Portugal were considered for inclusion in the
present substudy. Patients who lost their grafts within the first
year after transplantation and those without an evaluable bi-
opsy at the time of transplantation or at 1 year thereafter were
excluded from the study. Seventy patients had a functioning
graft at 1 year, and kidney biopsies were performed at the time
of transplantation and at 1 year after transplantation. Sixty-
four (91.4%) of those patients were evaluable (in 6 cases,
biopsy material could not be recovered for evaluation). All
patients included in this substudy received kidney transplants
from cadaveric donors. Table 1 shows the demographic char-
acteristics of patients included in the analysis. Both groups
were comparable for all data considered.
Evaluation of Renal Function
Renal function was analyzed at 1 year after transplan-
tation using serum creatinine and calculated creatinine clear-
ance (Nankivell method). Both parameters were compared
between treatment arms. Given the similar findings for these
two determinations, we will only present the serum creatinine
results.
Pathologic Evaluation
All patients who were evaluated had two kidney-graft bi-
opsies, the first at the time of transplantation and the second at 1
year after transplantation. The 128 graft biopsies were processed
using conventional techniques and staining with hematoxylin-
eosin, periodic-acid Schiff, and Masson’s trichrome. All slides
were evaluated by a central pathologist (author JMG) who was
blinded to the time of collection of the biopsy and the treatment
arm. Each biopsy was evaluated according to the Banff 1997
working classification (14) and the Chronic Allograft Damage
Index (CADI) classification (15). A Banff chronicity score
(Banff-CS) was calculated as the sum of the four chronic basic
lesions (chronic glomerular damage [cg]interstitial fibrosis
[ci]tubular fibrosis [ct]vascular intimal thickening [cv]), and
a CADI score was calculated as the sum of the six parameters
evaluated in this classification (inflammation [I]interstitial fi-
brosis [F]mesangial matrix increase [M]glomerular sclero-
sis [G]tubular atrophy [T]intimal proliferation [V]). Acute
lesions were also evaluated using the Banff criteria and were
compared between treatment arms with the objective of detect-
ing differences in inflammatory activity, the so-called subclinical
rejection, responsible for theoretical future chronic damage in
the long term.
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Evaluation of Histologic Graft Damage
Progression of any basic lesion was considered to be
present when a Banff or CADI score was higher in the 1-year
biopsy than in the pretransplant (baseline) biopsy of that pa-
tient, regardless of the severity of the lesion in the donor.
When the score was equal to or lower than the pretransplant
score, the patient was considered to have no progression of
the lesions. Chronicity scores ranged from 0 to 12 for
Banff-CS and from 0 to 18 for the CADI score. These results
were analyzed similarly for progression or no progression of
scores for each patient (pair of biopsies) analyzed. Because
Banff and CADI scores are semiquantitative parameters, the
percentage of patients with progression of chronicity findings
in each group (individual lesions and CS) was deemed the
most reliable parameter by which to evaluate the severity of
chronic graft damage.
TABLE 1. Demographic parameters and characteristics of patients and biopsy specimens in both treatment arms
Characteristic Group A Group B Total PValue
Sex, n (%) 0.385a
Male 24 (80) 24 (71) 48 (75)
Ethnic origin, n (%)
White 30 (100) 34 (100) 64 (100)
Age (years)
Mean (range) 44.4 (22–66) 47.1 (18–66) 45.8 (18–66) 0.352b
Standard deviation 12.3 10.4 11.3
Transplant, n (%) 0.630a
Primary 29 (97) 32 (94) 61 (95)
Secondary 1 (3) 2 (6) 3 (5)
Recipient CMV status, n (%) 0.244a
Positive 27 (90) 33 (97) 60 (94)
Primary etiology of renal failure, n (%) 0.123a
Autoimmune disease 1 (3) 0 1 (2)
Diabetes mellitus 1 (3) 4 (12) 5 (8)
Failure of previous graft 0 1 (3) 1 (2)
Glomerulonephritis 8 (27) 4 (12) 12 (19)
Hypertension 5 (17) 0 5 (8)
IgA nephropathy (Berger’s) 2 (7) 3 (9) 5 (8)
Interstitial nephritis/pyelonephritis 4 (13) 6 (18) 10 (16)
Other/unknown 8 (27) 15 (44) 23 (36)
Polycystic disease–kidney 1 (3) 1 (3) 2 (3)
Delayed graft function, n (%) 0.442a
Yes 4 (13) 7 (21) 11 (17)
Acute rejection, n (%) 0.209a
Yes 1 (3) 4 (12) 5 (8)
Number of HLA mismatches
Mean (range) 3.4 (1–5) 3.4 (1–5) 3.4 (1–5) 0.991b
Standard deviation 1.2 1 1.1
Ischemia time, hours
Mean (range) 20.3 (16–26) 18.8 (3–27) 19.5 (3–27) 0.218b
Standard deviation 2.8 5.7 4.6
Donor age, years
Mean (range) 39.6 (16–73) 38.2 (8–67) 38.4 (8–73) 0.906b
Standard deviation 16.3 16.5 16.3
Donor CMV status, n (%) 0.639a
Positive 25 (86) 27 (82) 52 (84)
Quality of biopsy specimens (%)
Adequate 38.1 43.9 41 0.286b
Marginal 29.7 26.3 28 0.320b
Unsatisfactory 32.2 29.8 31 0.251b
a Pearson chi-square test.
b Mann-Whitney test.
CMV, cytomegalovirus; Ig, immunoglobulin; HLA, human leukocyte antigen.
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Incidence and Severity of CAN
We calculated the prevalence of lesions compatible
with the diagnosis of CAN (according to Banff criteria) at the
time of transplantation and at 1 year after transplantation, as
well as the incidence of new cases of CAN that developed
during the first year. According to the Banff classification, the
diagnosis of CAN can be made when mild chronic interstitial
(ci1) and mild chronic tubular (ct1) changes are present. We
also analyzed the severity of CAN using grade I, grade II, and
grade III Banff criteria.
Statistical Analysis
Quantitative variables were described using the mean,
the standard deviation, and the range for each treatment
group. A Mann-Whitney test was used for testing statistical
mean differences between groups. A nonparametric test was
used because of the low sample size and to avoid the paramet-
ric assumption of normal distribution.
Qualitative variables were summarized with the cate-
gory frequencies and percentage for each treatment group. A
chi-square test was used for testing the statistical relation be-
tween the qualitative variables and the treatment groups. If
the expected frequency of more than the 20% of total cells of
the contingence table was less than 5, a Fisher exact test was
used.
For multiple comparisons, a Bonferroni adjustment




At 1 year after transplantation, or 9 months after ran-
domization, plasma creatinine was significantly lower in
group B than in group A (130.8 vs. 166.2 mol/L, respec-
tively, P0.05).
Quality of Biopsy Material
The mean number of glomeruli in the graft biopsies was
15.217.9 (range 0 –94), and the mean number of arteries
was 2.11.6 (range 0 – 8). According to Banff classification,
52 (41%) biopsies fulfilled the criteria for adequate specimen
with at least 10 glomeruli and 2 arteries; 36 (28%) biopsies
fulfilled the criteria for marginal specimen with more than 6
glomeruli and at least 1 artery; and 40 (31%) biopsies were
classified as unsatisfactory because of the presence of less than
7 glomeruli or no arteries present for histologic evaluation.
The percentage of adequate, marginal, and unsatisfactory
specimens was comparable in both groups (Table 1). Twenty-
three of the basal biopsies (of 64) were wedge biopsies with a
similar distribution in both groups (12 in group A and 11 in
group B).
Progression of Pathologic Lesions: Banff
Classification
A higher proportion of patients showed progression
(increase in severity) of chronic interstitial (ci), tubular (ct),
and vascular (cv) lesions in group A compared with group B
(70% vs. 40.9%, respectively, for ci, P0.05; 70% vs. 47.8%,
respectively, for ct, P0.05; and 29.4% vs. 25%, respectively,
for cv, PNS). Progression of chronic glomerular (cg) lesions
and arterial hyalinosis (ah) was not significantly different be-
tween both treatment arms (9.1% vs. 0%, respectively, for cg,
PNS; and 19% vs. 10.5%, respectively, for ah, PNS) (Fig.
1).
The differences in progression of chronic lesions be-
came more evident when they were compared with the Banff
chronicity score, the sum of chronic glomerular, interstitial,
tubular, and vascular lesions. Figure 1 also shows the percent-
age of patients with progression of Banff-CS in both groups:
76.5% of patients in group A versus 31.3% in group B dem-
onstrated progression of chronic lesions (P0.01).
No significant differences in Banff acute lesions were
observed between treatment arms. Progression of interstitial
infiltrate (i) and glomerular changes (g) were not more fre-
quent in any group (36.8% vs. 28.6%, PNS, and 15% vs.
27.3%, PNS, respectively). Minimal differences in tubular
(t) and vascular (v) lesions were observed (PNS). No cases
at 1-year fulfilled the criteria for the diagnosis of acute rejec-
tion, whereas in four cases, pathologic findings were consis-
tent with the diagnosis of borderline changes (2 in group A
and 2 in group B).
When unsatisfactory specimens were excluded from
the analysis and only adequate and marginal cases were con-
sidered, the results were consistent with what was previously
described. In particular, Banff chronic interstitial and tubular
differences (progression of ci and ct) were more pronounced
(Table 2).
Progression of Pathologic Lesions: CADI
Classification
Evaluation of biopsies using the CADI classification
showed results similar to those analyzed using the Banff clas-
sification. Interstitial fibrosis (F) and tubular atrophy (T),
progressed more frequently in group A patients (68.4% vs.
40.9% for F, P0.05; 68.4% vs. 45.5% for T, P0.05). There
FIGURE 1. Percentage of patients with progression of
Banff chronic individual lesions and Banff-chronicity score
(cgcictcv) from the time of transplantation to the first
year after transplantation. *P0.05 between groups. cg,
chronic glomerular damage; ci, interstitial fibrosis; ct, tu-
bular fibrosis; cv, vascular intimal thickening.
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were no significant differences in intimal proliferation (V)
(31.3% vs. 23%, PNS), glomerular changes (G) (5.3% vs.
14.3%, PNS), interstitial infiltration (I), or mesangial
changes (M). CADI score results were similar to those of
Banff-CS: 75% of patients in group A showed progression of
CADI score versus 43.8% in group B (P0.05) (Fig. 2).
Incidence and Severity of CAN
Using the Banff classification, the diagnosis of CAN
(any grade) at 1 year after transplantation was higher, but not
statistically significant, in the group remaining on CsA
(70.8% in group A and 59.3% in group B; P0.25). The di-
agnosis of CAN was made more often in pretransplant biop-
sies in group B compared with group A (21.7% vs. 9.5%,
respectively; P0.15). However, 65% of patients in group A
who did not have findings compatible with CAN in pretrans-
plant biopsies developed changes consistent with CAN at 1
year, whereas only 31.8% of such cases in group B progressed
to CAN at 1 year (P0.05). Furthermore, the severity of CAN
at 1 year was higher in group A compared with group B
(35.3% vs. 25%, respectively, Banff grade III), although the
difference was not statistically significant (Fig. 3).
DISCUSSION
The results of this study demonstrate that the elimina-
tion of CsA at 3 months after transplantation has a significant
beneficial effect on the development and progression of
chronic allograft damage during the first year after transplan-
tation, despite the slightly higher rate of acute rejection ob-
served in this group (10). This benefit may be a consequence
of the prevention of chronic CsA toxicity.
The direct contribution of CNI toxicity to the progres-
sive deterioration of renal function is difficult to establish.
However, it has been demonstrated that renal function con-
tinues to improve for months after CNI discontinuation (13),
which suggests a direct correlation that may be associated
with a reduction in the production of profibrogenic media-
tors such as tumor growth factor (TGF)- (16). This media-
tor has been implicated in the development of tubulointersti-
tial fibrosis, the most characteristic finding associated with
chronic CsA toxicity (17, 18).
The clinical results obtained from the RMR Study have
clearly demonstrated that CsA elimination after the third
postransplantation month is a safe procedure in the presence
TABLE 2. Percentage of pathologic lesions in the
subgroup of patients with only adequate or marginal
biopsy specimens
Group A Group B PValue
Banff-cg 0 7.7 NS
Banff-ci 70 15 0.05
Banff-ct 70 23 0.05
Banff-cv 20 23 NS
Banff-ah 10 15 NS
Banff-CS 70 23 0.05
CADI-I 60 61 NS
CADI-F 70 15 0.05
CADI-M 40 31 NS
CADI-G 0 15 NS
CADI-T 70 23 0.05
CADI-V 20 23 NS
CADI score 70 38 NS
NS, not significant; cg, chronic glomerular damage; ci, interstitial fibro-
sis; ct, tubular fibrosis; cv, vascular intimal thickening; CADI, Chronic Allo-
graft Damage Index; I, inflammation; F, interstitial fibrosis; M, masangial
matrix increase; G, glomerular sclerosis; T, tubular atrophy; V, intimal pro-
liferation.
FIGURE 2. Percentage of patients with progression of
CADI individual lesions and Chronic Allograft Damage In-
dex (CADI) score (IFMGTV) from the timeof trans-
plantation to the first year after transplantation. *P0.05
between groups. I, inflammation; F, interstitial fibrosis; M,
mesangial matrix increase; G, glomerular sclerosis; T, tu-
bular atrophy; V, intimal proliferation.
FIGURE 3. Distribution of patients diagnosed with
chronic allograft nephropathy (CAN) at 1 year after trans-
plantation according to its severity. *No significant differ-
ences between groups.
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of SRL and results in an improvement in renal function (10).
The 2-year results demonstrated continuous long-term im-
provement in renal function after CsA cessation, with the
difference in renal function (mean serum creatinine) between
the two treatment arms increasing from 15.7mol/L at 1 year
to 28.4 mol/L at 2 years (13). The hemodynamic effect of
CsA elimination alone may not be responsible for this main-
tained and progressive improvement in renal function but
may indicate a reduction in chronic graft CsA toxicity, which
is manifested by chronic tubular and interstitial lesions. Fur-
thermore, results from the Collaborative Transplant Study by
Opelz et al. (19) indicate that improvement in blood pressure,
as observed in the CsA elimination group (10), may be an
independent factor responsible for better long-term kidney-
graft outcome. Nevertheless, an improvement in long-term
graft outcome should be associated with a reduction in graft
pathologic lesions and a subsequent decrease in the incidence
and severity of CAN. Our previous report suggested this hy-
pothesis but the results were inconclusive because of limita-
tions in the study design (11).
Our current study analyzed a subpopulation of the pa-
tients enrolled in the RMR Study, specifically those in Spain
and Portugal. Approximately 80% of these patients had two
biopsies performed. We performed a blinded reanalysis of
most of these cases (64/70) that were also evaluated in the
previous report, which corresponds to 128 of 140 biopsies.
The pathologist received all samples at the same time and was
unaware of treatment arm assignment as well as the time of
biopsy. The blinded nature of the analysis is important be-
cause pathologists have a tendency to underestimate lesions
they consider a consequence of pretransplant donor damage,
which subsequently may influence the final results when
comparing pretransplant and 1-year biopsies. All biopsies
were reread in a short period of time, approximately 3 weeks.
Surprisingly, the results obtained in this reanalysis, although
similar to those published in the previous article, demon-
strate more statistical significance. The criteria of interpreta-
tion from 10 different pathologists in the previous study
could account for the difference in results.
One important factor to consider in the evaluation of
chronic pathologic damage and the effect of immunosup-
pressive therapy is the presence of preexisting lesions in the
donor that are indistinguishable from new lesions that de-
velop after transplantation. The severity of such lesions can be
correlated with the age of the donor and the existence of
pathologic conditions such as arterial hypertension or diabe-
tes mellitus. When comparing the severity of chronic changes
in protocol biopsies at 1 year after transplantation between
the two treatment arms, those pretransplant lesions must not
be considered. For that reason, every case must be evaluated
separately, comparing the severity of lesions in the 1-year bi-
opsy with that in the baseline biopsy. Because lesions are eval-
uated using semiquantitative (not quantitative) scales (Banff
and CADI), it is not possible to perform mathematical oper-
ations to subtract the value in the pretransplant biopsy from
that in the 1-year biopsy. For that reason, we considered the
existence of progression between biopsies in every lesion and
then calculated the percentage of patients with progression as
the optimal approach to the problem.
A potential shortcoming of our study is that we ana-
lyzed a smaller number of patients who represented a sub-
group of patients from the RMR Study. However, we had a
higher rate of patients who had two biopsies performed
(80%) compared with the other participating centers (50% in
the whole RMR Study). Also, the renal-function parameters
of patients evaluated in this substudy were similar to those
observed in our previous report (11). The direct effect of SRL
in the reduction of chronic damage, because of its recognized
antiproliferative effect, is difficult to asses in this study be-
cause both treatment arms received the drug (20). Neverthe-
less, it is important to consider that SRL levels after random-
ization in the third month were maintained at a higher level in
group B, approximately two times that in group A, and this
could be of some importance with respect to this effect.
Another potential shortcoming of the study is the risk
of bias based on the actual distribution of adequate, marginal,
and unsatisfactory biopsies between the two groups of pa-
tients. A significant imbalance in the proportion of unsatis-
factory biopsies might be responsible for incorrect results. As
Table 1 shows, this problem is clearly absent in our series
because the distribution of the biopsy material in both groups
according to quality is clearly comparable.
Stallone et al. (21) recently reported results similar to
those presented in this study but in a smaller group of patients
and with a less extensive biopsy analysis. Our study confirms
the differences in the prevalence and severity of CAN but also
demonstrated that the development of new cases after trans-
plantation is increased when CsA is maintained, regardless of
the severity of pathologic lesions in baseline biopsies. In ad-
dition, the analysis of individual pathologic lesions showed a
significant benefit with CsA elimination in the rate of pro-
gression of tubular and interstitial lesions. These two lesions
are associated with chronic CsA toxicity and are more directly
related to the progressive deterioration of graft function.
Nevertheless, we have no explanation for the absence of im-
provement in group B with respect to arteriolar hyalinosis, a
lesion that clearly correlates with long-term CsA toxicity.
Analysis of acute lesions showed no differences be-
tween groups. Therefore, subclinical rejection with a subse-
quent risk of graft damage (22, 23) caused by suboptimal
immunosuppression in patients who had CsA withdrawn was
considered not to be present—this is a very interesting as-
pect—and contrasts with the results observed in some other
trials where a reduced but significant number of cases show
lesions compatible with subclinical rejection in protocol
biopsies.
In conclusion, early elimination of CsA after transplan-
tation in the presence of SRL results in a reduction both in the
progression of pathologic lesions and in the appearance of
new cases and severity of CAN, probably because of preven-
tion of chronic nephrotoxicity. This benefit, combined with
the improvement in renal function, may result in a subse-
quent improvement in long-term graft survival. Future re-
sults from the ongoing RMR Study (pathologic data at 3 years
after transplant and clinical results at 5 years) will contribute
significantly to the clarification of the benefits with cal-
cineurin-free immunosuppression.
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